Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.
about
Beta class II tubulin predominates in normal and tumor breast tissues.Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppressionA collection of breast cancer cell lines for the study of functionally distinct cancer subtypesDNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancersBreast cancer cell lines: friend or foe?A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissueCancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer MedicineTechnologies for deriving primary tumor cells for use in personalized cancer therapySteady-state acceptor fluorescence anisotropy imaging under evanescent excitation for visualisation of FRET at the plasma membraneSMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele lossA genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignanciesDistinct patterns of somatic alterations in a lymphoblastoid and a tumor genome derived from the same individualDiscovering biological connections between experimental conditions based on common patterns of differential gene expressionPersonalized chemotherapy profiling using cancer cell lines from selectable miceUse of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET.Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: mutation analysisNeisseria gonorrhoeae elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells.PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.The effect of chemotherapeutic agents on telomere length maintenance in breast cancer cell lines.X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation.StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.Identification of 5 novel genes methylated in breast and other epithelial cancers.Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.Cytoglobin, the newest member of the globin family, functions as a tumor suppressor geneAltered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.Segtor: rapid annotation of genomic coordinates and single nucleotide variations using segment trees.Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cellsLung cancer cell lines as tools for biomedical discovery and researchSMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent mannerEngineering toxin-resistant therapeutic stem cells to treat brain tumorsG&T-seq: parallel sequencing of single-cell genomes and transcriptomes.The relative timing of mutations in a breast cancer genome.Macrophages induce COX-2 expression in breast cancer cells: role of IL-1β autoamplificationThe characterization of cell line crl-2335 as a Basal-like breast carcinoma model.Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells.An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models.Secondary mutations of BRCA1/2 and drug resistanceLung cancer cell lines: Useless artifacts or invaluable tools for medical science?
P2860
Q28872477-4F4C1ED9-E2F5-4335-906C-8111554389F6Q28872486-354FA79B-3B74-4940-BF98-F0AFD7D1D7AFQ54881517-E7B7D4AA-4E43-4FAE-A014-9A5C4665C28BQ54881518-4B74351C-3B5A-437B-BA49-5D7F0845677AQ54881519-6C6B0256-824C-4CB2-A1BD-9C0FB2A9BE4DQ54881530-6878A2FC-9D2A-4F9A-A3AA-9EAF32FAB285Q54881531-39E0C7A6-620A-4E78-9452-31A6B76D6ADAQ54881536-7C1FBD1E-A021-4536-AF18-7EADFD7283C0Q54881537-A6F9EDC9-240D-4402-95A3-4C02F985DD15Q54881565-4C4F539D-8242-4435-882D-6432A823E052Q54881566-6F88C348-DAC2-4EEF-AC75-EBC97B2D6E2AQ54881567-B719BAF3-205D-4599-B7F3-795885791D64Q54881570-F4E88B1F-59D0-4A14-9976-9B5A908AB839Q54881571-C3CD7BEC-B3E5-4E1C-A662-086E15238A44Q54881583-74E9E6F9-548B-496A-A5B1-08434DB2483AQ54881587-BF73677E-0E0A-4680-B6A9-DAB75EB6C4B3Q54881591-AA216471-6803-4B8D-8EA3-DAA47EE6981BQ54881592-D96FF969-A5A7-4D8A-A5CA-1D68EB61CB4EQ54881602-83E45843-2B04-47A6-8EFA-60F6D40DC702Q54881603-DB7651E7-1A6D-476E-8275-9311E97A5D60Q54881605-2A5A9389-F3D3-4C4C-AB1A-31533681191DQ54881618-085CCBC6-54D5-40ED-B3E4-83BACB940F86Q54881619-BA5C32F7-B480-4458-90BD-2676C4E38BBCQ54881628-A3E862AD-69EF-4B9A-8FCA-7200239957EEQ54881634-2EF2FB3A-082E-4D50-80AD-9C70ABEDE7CAQ54881635-0956FDF7-CF60-4595-8D1E-1509835BCC72Q54881636-8DB42A10-A849-4106-9099-D5B25205A94FQ54881637-349363EE-AC54-4ACE-8666-B49B5EFE7903Q54881638-3131AD40-CF02-41CE-AB3B-7A612025BA3EQ54881712-E2FBE320-091F-4859-8BC4-CF947E7B04C6Q54881713-D9ABE499-EE8B-4614-AA5D-6E1E17A37A92Q54881772-012B8D3C-2B87-48A3-8A57-C70CDA8EC035Q54881774-EB56196A-CE8D-4029-BB5D-52CE8E12B00F
P1343
Q21195178-C9FC8540-D16A-47C8-BCFB-A885E79C08E0Q24291194-8DE9A0A7-A2A5-4054-B5DC-B441E051AC78Q24647928-5EC531FE-FB02-45B2-A75D-C4D5DF0D752FQ24650975-EBE4BD76-D73F-4D25-9759-00EC15A40936Q24795678-F3341CF1-22E6-4D14-B363-DDE8B6F40CB2Q24797970-94F32BB3-B443-4DC8-A46A-F5BCBC34EE3FQ26800337-981D18A1-6041-42B3-9978-D378509E49E8Q26829581-AB7078F2-B3BB-4533-9CD7-883A8B36E36BQ27334709-BD84C5A3-EFA0-4DED-9C2C-BE5232484166Q27851475-010DD0CC-6235-4CAC-8E37-F774EEE21316Q28189969-27EE5E75-8291-4C8A-864F-AF202228FAFDQ28343524-8E2841F1-14E3-43A0-81D4-F41B62478422Q28469084-B4CF23A5-B20F-4976-9598-BD704554AF62Q28741663-86620B83-31EA-4380-B7EE-C4EA5209263CQ28743395-6ACC1466-8989-4465-875D-AB8C5E2AD674Q30538234-6D1F8707-689E-4C30-B85D-6CF9DB90E362Q30659434-579E832C-4E89-43B8-A1D9-7C976F6DABC6Q33592683-0F841834-8BF0-4E47-A610-997E62AADA85Q33600246-DCCDFD73-5DA1-4C87-9CCE-3C7F884E742EQ33610437-0AFD6079-83C9-45BA-B655-8F3A5D2B5E64Q33651543-00D19F34-83B7-4440-9F3E-A72F5767E647Q33658266-28076E84-15D5-44CC-9627-2EB6995E5DD4Q33679597-6E5DCF1B-CACF-4D15-9788-B0693692EFD0Q33737079-BBA543B9-AFC2-463C-BB1B-ED0960223628Q33743601-6CFBB318-DA3C-4944-A052-EF00E98C677FQ33769833-5100A336-90C7-4F1E-A973-D0D41FE05299Q33865095-AE5CBDF8-026D-4EA3-94D0-BBF474B45B57Q34070504-40B8D19C-2EE4-4FD7-9B4B-CE17375CC204Q34103923-64630F8B-3B60-4E80-B662-34105198F01DQ34110617-3DA0069B-6F6A-44F7-9DD5-2DB417F3D5DCQ34229779-3B93CE41-B9EA-41CE-AB93-9BAD213B478FQ34444939-1751F990-1F77-4289-B3A9-26714E7D706DQ34473774-77D714FB-BAE7-4C2A-AB02-36E564484954Q34769556-312E81CF-F995-497F-BF51-9CCB78B90B93Q34913841-B30606E6-DA0B-4B2D-A9F6-C19DAD46DA97Q34965636-8F730F84-044B-4DB6-AE60-3F731EC6A2E0Q34970719-328F7FEC-E0BC-4E0A-BA02-A00918CBD78AQ34980384-B5776EB3-CF3A-4C38-BF4D-8BA4A3324020Q34983549-C5E95F8B-4772-452A-BA11-CE69602DD231Q35033316-5E6C4743-2FBF-481D-AB95-C548D39312A1
P2860
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Characterization of paired tum ...... m patients with breast cancer.
@en
type
label
Characterization of paired tum ...... m patients with breast cancer.
@en
prefLabel
Characterization of paired tum ...... m patients with breast cancer.
@en
P2093
P2860
P4510
P1476
Characterization of paired tum ...... m patients with breast cancer.
@en
P2093
A F Gazdar
A M Leitch
D Kodagoda
G Tomlinson
H T Cunningham
I I Wistuba
L Gollahon
P2860
P304
P356
10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
P577
1998-12-01T00:00:00Z